Page 911 - Williams Hematology ( PDFDrive )

886 Part VI: The Erythrocyte Chapter 57: Primary and Secondary Erythrocytoses 887

74. Simonson TS, Yang Y, Huff CD, et al: Genetic evidence for high-altitude adaptation in 109. Friedrich CA: Von Hippel-Lindau syndrome. A pleomorphic condition. Cancer 86(11
Tibet. Science 329(5987):72, 2010. Suppl):2478, 1999.
75. Yi X, Liang Y, Huerta-Sanchez E, et al: Sequencing of 50 human exomes reveals adapta- 110. Haase VH, Glickman JN, Socolovsky M, et al: Vascular tumors in livers with targeted
tion to high altitude. Science 329(5987):75, 2010. inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A
76. Beall CM, Cavalleri GL, Deng L, et al: Natural selection on EPAS1 (HIF2alpha) associ- 98(4):1583, 2001.
ated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U 111. Krieg M, Marti HH, Plate KH: Coexpression of erythropoietin and vascular endothe-
S A 107(25):11459, 2010. lial growth factor in nervous system tumors associated with von Hippel-Lindau tumor
77. Huerta-Sanchez E, Jin X, Asan, et al: Altitude adaptation in Tibetans caused by intro- suppressor gene loss of function. Blood 92(9):3388, 1998.
gression of Denisovan-like DNA: Nature 512(7513):194, 2014. 112. Richards FM: Molecular pathology of von Hippel Lindau disease and the VHL tumour
78. Krause J, Fu Q, Good JM, et al: The complete mitochondrial DNA genome of an suppressor gene. Expert Rev Mol Med 2001:1, 2001.
unknown hominin from southern Siberia. Nature 464(7290):894, 2010. 113. Couvé S, Ladroue C, Laine C, et al: Genetic evidence of a precisely tuned dysregu-
79. Abi-Rached L, Jobin MJ, Kulkarni S, et al: The shaping of modern human immune lation in the hypoxia signaling pathway during oncogenesis. Cancer Res 74(22):6554,
systems by multiregional admixture with archaic humans. Science 334(6052):89, 2011. 2014.
80. Lorenzo FR, Rili G, Simonson T, et al: A novel PHD2 mutation associated with Tibetan 114. Percy MJ, Zhao Q, Flores A, et al: A family with erythrocytosis establishes a role for
genetic adaptation to high altitude hypoxia. ASH 52nd Annual Meeting, Orlando, FL, prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A
2010. 103(3):654, 2006.
81. Lorenzo FR, Huff C, Myllymaki M, et al: A genetic mechanism for Tibetan high- 115. Bento C, Percy MJ, Gardie B, et al: Genetic basis of congenital erythrocytosis: Mutation
altitude adaptation. Nat Genet 46(9):951, 2014. update and online databases. Hum Mutat 35(1):15, 2014.
82. Jefferson JA, Escudero E, Hurtado ME, et al: Excessive erythrocytosis, chronic moun- 116. Lorenzo FR, Yang C, Ng Tang Fui M, et al: A novel EPAS1/HIF2A germline mutation in
tain sickness, and serum cobalt levels. Lancet 359(9304):407, 2002. a congenital polycythemia with paraganglioma. J Mol Med (Berl) 91(4):507, 2013.
83. Goldwasser E, Jacobson LO, Fried W, et al: Mechanism of the erythropoietic effect of 117. Russell RC, Sufan RI, Zhou B, et al: Loss of JAK2 regulation via a heterodimeric VHL-
cobalt. Science 125(3257):1085, 1957. SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med 17(7):845, 2011.
84. Bernardi L, Roach RC, Keyl C, et al: Ventilation, autonomic function, sleep and ery- 118. Kaufmann KB, Grunder A, Hadlich T, et al: A novel murine model of myeloprolifera-
thropoietin. Chronic mountain sickness of Andean natives. Adv Exp Med Biol 543:161, tive disorders generated by overexpression of the transcription factor NF-E2. J Exp Med
2003. 209(1):35, 2012.
85. Murray JF: Classification of polycythemic disorders. With comments on the diagnostic 119. Maran J, Jedlickova K, Stockton D, Prchal JT: Finding the novel molecular defect in a
value of arterial blood oxygen analysis. Ann Intern Med 64:892, 1966. family with high erythropoietin autosomal dominant polycythemia. Blood 102:162b,
86. Kuhl W: History of clinical research on the sleep apnea syndrome. The early days of 2003.
polysomnography. Respiration 64 Suppl 1:5, 1997. 120. Hammond D, Winnick S: Paraneoplastic erythrocytosis and ectopic erythropoietins.
87. Block AJ, Boysen PG, Wynne JW, et al: Sleep apnea, hypopnea and oxygen desaturation Ann N Y Acad Sci 230:219, 1974.
in normal subjects. A strong male predominance. N Engl J Med 300(10):513, 1979. 121. Navarro J, Aguilera A, Liano F, et al: Phlebotomy for polycythemia associated with
88. Moore-Gillon JC, Treacher DF, Gaminara EJ, et al: Intermittent hypoxia in patients with acquired cystic renal disease in a patient on hemodialysis. Nephron 62(1):110, 1992.
unexplained polycythaemia. Br Med J (Clin Res Ed) 293(6547):588, 1986. 122. Da Silva JL, Lacombe C, Bruneval P, et al: Tumor cells are the site of erythropoietin
89. Smith JR, Landaw SA: Smokers’ polycythemia. N Engl J Med 298(1):6, 1978. synthesis in human renal cancers associated with polycythemia. Blood 75(3):577, 1990.
90. Stonesifer LD: How carbon monoxide reduces plasma volume. N Engl J Med 299(6):311, 123. Lal A, Rice A, al Mahr M, et al: Wilms tumor associated with polycythemia: Case report
1978. and review of the literature. J Pediatr Hematol Oncol 19(3):263, 1997.
91. Cartier P, Labie D, Leroux JP, et al: [Familial diphosphoglycerate mutase deficiency: 124. Grignon DJ, Eble JN: Papillary and metanephric adenomas of the kidney. Semin Diagn
Hematological and biochemical study] [in French]. Nouv Rev Fr Hematol 12(3):269, Pathol 15(1):41, 1998.
1972. 125. Fisher JW, Samuels AI: Relationship between renal blood flow and erythropoietin pro-
92. Lichtman MA, Murphy MS and Adamson JW: Detection of mutant hemoglobins with duction in dogs. Proc Soc Exp Biol Med 125(2):482, 1967.
altered affinity for oxygen. A simplified technique. Ann Intern Med 84(5):517, 1976. 126. Beebe HG, Chesebro K, Merchant F, et al: Results of renal artery balloon angioplasty
93. Agarwal N, Mojica-Henshaw MP, Simmons ED, et al: Familial polycythemia caused by limit its indications. J Vasc Surg 8(3):300, 1988.
a novel mutation in the beta globin gene: Essential role of P50 in evaluation of familial 127. Mrug M, Julian BA, Prchal JT: Angiotensin II receptor type 1 expression in erythroid
polycythemia. Int J Med Sci 4(4):232, 2007. progenitors: Implications for the pathogenesis of postrenal transplant erythrocytosis.
94. Xia M, Huang T, Sun Y, et al: Identification of chemical compounds that induce HIF-1 Semin Nephrol 24(2):120, 2004.
alpha activity. Toxicol Sci 112(1):153, 2009. 128. Danovitch GM, Jamgotchian NJ, Eggena PH, et al: Angiotensin-converting enzyme
95. Sergeyeva A, Gordeuk VR, Tokarev YN, et al: Congenital polycythemia in Chuvashia. inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and
Blood 89(6):2148, 1997. observation of mechanism. Transplantation 60(2):132, 1995.
96. Tomasic NL, Piterkova L, Huff C, et al: The phenotype of polycythemia due to Croatian 129. Mrug M, Stopka T, Julian BA, et al: Angiotensin II stimulates proliferation of normal
homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash poly- early erythroid progenitors. J Clin Invest 100(9):2310, 1997.
cythemia (VHL 598C>T:R200W). Haematologica 98(4):560, 2013. 130. Glicklich D, Burris L, Urban A, et al: Angiotensin-converting enzyme inhibition
97. Lanikova L, Lorenzo F, Yang C, et al: Novel homozygous VHL mutation in exon 2 is induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in
associated with congenital polycythemia but not with cancer. Blood 121(19):3918, 2013. posttransplantation erythrocytosis. J Am Soc Nephrol 12(9):1958, 2001.
98. Lorenzo FR, Yang C, Lanikova L, et al: Novel compound VHL heterozygosity (VHL 131. Gossmann J, Burkhardt R, Harder S, et al: Angiotensin II infusion increases plasma
T124A/L188V) associated with congenital polycythaemia. Br J Haematol 162(6):851, erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney
2013. Int 60(1):83, 2001.
99. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al: Congenital disorder of oxygen sens- 132. Thevenod F, Radtke HW, Grutzmacher P, et al: Deficient feedback regulation of ery-
ing: Association of the homozygous Chuvash polycythemia VHL mutation with throm- thropoiesis in kidney transplant patients with polycythemia. Kidney Int 24(2):227,
bosis and vascular abnormalities but not tumors. Blood 103:3924, 2004. 1983.
100. Percy MJ, McMullin MF, Jowitt SN, et al: Chuvash-type congenital polycythemia in 4 133. Friman S, Nyberg G, Blohme I: Erythrocytosis after renal transplantation; treatment by
families of Asian and Western European ancestry. Blood 102(3):1097, 2003. removal of the native kidneys. Nephrol Dial Transplant 5(11):969, 1990.
101. Bento MC, Chang KT, Guan Y, et al: Congenital polycythemia with homozygous and 134. Cole J, Ertoy D, Lin H, et al: Lack of angiotensin II-facilitated erythropoiesis causes
heterozygous mutations of von Hippel-Lindau gene: Five new Caucasian patients. anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 106(11):1391,
Haematologica 90(1):128, 2005. 2000.
102. Cario H, Schwarz K, Jorch N, et al: Mutations in the von Hippel-Lindau (VHL) tumor 135. Venencie PY, Puissant A, Boffa GA, et al: Multiple cutaneous leiomyomata and erythro-
suppressor gene and VHL-haplotype analysis in patients with presumable congenital cytosis with demonstration of erythropoietic activity in the cutaneous leiomyomata. Br
erythrocytosis. Haematologica 90(1):19, 2005. J Dermatol 107(4):483, 1982.
103. Collins TS, Arcasoy MO: Iron overload due to X-linked sideroblastic anemia in an 136. Trimble M, Caro J, Talalla A, et al: Secondary erythrocytosis due to a cerebellar heman-
African American man. Am J Med 116(7):501, 2004. gioblastoma: Demonstration of erythropoietin mRNA in the tumor. Blood 78(3):599,
104. Pastore Y, Jedlickova K, Guan Y, et al: Mutations of von Hippel-Lindau tumor-suppressor 1991.
gene and congenital polycythemia. Am J Hum Genet 73(2):412, 2003. 137. McFadzean AJS, Todd D, Tsang, KC: Polycythemia in primary carcinoma of the liver.
105. Pastore YD, Jelinek J, Ang S, et al: Mutations in the VHL gene in sporadic apparently Blood 13:427, 1958.
congenital polycythemia. Blood 101(4):1591, 2003. 138. Davidson CS: Hepatocellular carcinoma and erythrocytosis. Semin Hematol 13(2):115,
106. Semenza GL: HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13(2):167, 1976.
2001. 139. Muta H, Funakoshi A, Baba T, et al: Gene expression of erythropoietin in hepatocellular
107. Miasnikova GY, Sergueeva AI, Nouraie M, et al: The heterozygote advantage of the carcinoma. Intern Med 33(7):427, 1994.
Chuvash polycythemia VHLR200W mutation may be protection against anemia. Hae- 140. Shulkin BL, Shapiro B, Sisson JC: Pheochromocytoma, polycythemia, and venous
matologica 96(9):1371, 2011. thrombosis. Am J Med 83(4):773, 1987.
108. Cramer T, Yamanishi Y, Clausen BE, et al: HIF-1alpha is essential for myeloid cell- 141. Zhuang Z, Yang C, Lorenzo F, et al: Somatic HIF2A gain-of-function mutations in para-
mediated inflammation. Cell 112(5):645, 2003. ganglioma with polycythemia. N Engl J Med 367(10):922, 2012.

Kaushansky_chapter 57_p0871-0888.indd 886 9/18/15 9:37 AM